Ruby M. Van Stein (Netherlands)
Antoni van Leeuwenhoek - Netherlands Cancer Institute
Gynecologic Oncology
Ruby van Stein was born on September 29, 1992 in Almere, the Netherlands. In 2011, she moved to Belgium to study Biomedical Sciences at the University of Antwerp. A year later she started as a medical student at the Vrije Universiteit Amsterdam, the Netherlands. During her studies, she did a clinical internship in Paramaribo, Suriname. Her scientific interest was raised during her bachelors, when she volunteered to work as a research assistant at the pediatric department of Amsterdam UMC. In the following years, she was involved in research on analysis of fecal volatile organic compounds in preterm infants. Ruby obtained her medical degree in 2018 and started working as resident not in training at the department of gynecology and obstetrics of Spaarne Gasthuis Haarlem. In 2019, she started as a PhD student at the department of gynecologic oncology of the Netherlands Cancer Institute under the supervision of Prof. Dr. G.S. Sonke and Dr. W.J. van Driel, investigating ovarian cancer and treatment with hyperthermic intraperitoneal chemotherapy. She coordinates the national OVHIPEC implementation study in 10 hospitals, and the multicenter international randomized controlled OVHIPEC-2 trial.

Presenter of 1 Presentation

 Conference Calendar

USE AND EARLY POSTOPERATIVE OUTCOMES OF HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY FOR OVARIAN CANCER IN CLINICAL PRACTICE

Session Name
0670 - Focused Plenary – Ovarian Cancer (ID 26)
Session Type
Plenary Session
Date
09/30/2022
Session Time
08:05 AM - 09:05 AM
Room
Hall 405
Session Icon
On-Demand
Presenter
Lecture Time
08:23 AM - 08:31 AM
Onsite or Pre-Recorded
Onsite

Abstract

Objectives

The OVHIPEC-1 trial demonstrated improved recurrence-free and overall survival with the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery (CRS) in patients with stage III epithelial ovarian cancer (EOC). In 2019, HIPEC for this patient population was implemented in ten Dutch HIPEC-centers. This study aimed to examine the use and early postoperative outcomes of HIPEC in a real-world setting.

Methods

This observational multicenter study used data from the Dutch Gynaecological Oncology Audit including all 668 Dutch patients with stage III EOC who underwent complete or optimal interval CRS between 2019-2021. We examined use of HIPEC and compared early postoperative outcomes with and without HIPEC while accounting for differences in baseline characteristics.

Results

During the study period, HIPEC use increased from 49% to 64%. Uptake varied between geographical regions from 40%-76%. Age, performance status, and result of CRS were associated with HIPEC use (Table 1). Early postoperative outcomes are shown in Table 2. In multivariable logistic regression analysis, HIPEC was associated with a prolonged length of hospital stay (>7 days) (OR 3.9, 95% CI 2.5-5.3, p<0.001) and increased complications (any complication) (OR 1.5, 95% CI 1.0-2.1, p=0.026). However, no effect was seen on incidence of severe complications (Clavien-Dindo ≥grade 3) (OR 0.7, 95% CI 0.3-1.5, p=0.378) and 30-day-mortality.

table 1.jpg

table 2.jpg

Conclusions

Use of HIPEC increased substantially in the Netherlands since its introduction in 2019. The effect of HIPEC on early postoperative outcomes in a real-world setting and clinical trial setting are comparable. Future analyses will show whether this also accounts for survival outcomes.

Hide